Broad Spectrum antiviral activity of REPLICor’s antiviral drugs

 

REPLICor is developing its drug as a broad spectrum antiviral that could generate an important impact in the medical field.  This drug is the first broad-spectrum antiviral compound ever described having activity in at least 12 families of viruses.

 

 

Hepatitis Viruses

Activity

Activity

in vitro

in vivo

Hepatitis B (HBV)

Yes

Yes

Duck HBV

Yes

Yes

Hepatitis C (HCV)

Yes

Yes

 

 

 

Respiratory Viruses

Activity

Activity

in vitro

in vivo

Influenza A

Yes

Yes

Influenza B

Yes

 

Respiratory syncytial (RSV)

Yes

Yes

Human metapneumovirus

Yes

 

 

 

 

Herpes Viruses

Activity

Activity

in vitro

in vivo

Herpes simplex 1 (HSV-1)

Yes

 

Herpes simplex 2 (HSV-2)

Yes

Yes

Cytomegalovirus (CMV)

Yes

Yes

Varicella zoster (VZV)

Yes

 

Epstein-Barr (EBV)

Yes

 

Human herpes HHV-6A and 6B

Yes

 

 

 

 

Immunodeficiency Viruses

Activity

Activity

in vitro

in vivo

HIV-1

Yes

 

Friend leukemia

 

Yes

 

 

 

Biodefense Viruses

Activity

Activity

in vitro

in vivo

Ebola

Yes

Yes

Marburg

Yes

 

Lassa fever

Yes

Yes

Vaccinia (smallpox surrogate)

Yes

Yes

Mousepox (ectromelia)

Yes

 

 

 

 

Emerging & Tropical Viruses

Activity

Activity

 

in vitro

in vivo

Hantavirus

Yes

 

Hantaan

Yes

 

Crimean Congo Hem. fever

Yes

 

Rift Valley Fever

Yes

 

West Nile

Yes

 

Yellow fever

Yes

 

Dengue

Yes

 

Tick born encephalitis

Yes

 

Western equine encephalitis

Yes

 

Venezuelan equine encephalitis

 Yes